Business ❯ Pharmaceuticals

Acquisitions

Drug Development Sanofi Mergers and Acquisitions Corporate Strategy Merck Novartis Biotechnology Eli Lilly Pfizer Merck & Co.

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

The buyout expands UCB's push into T‑cell engager drugs for autoimmune diseases.

Stories older than 24h

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Pfizer Sues to Block Novo Nordisk’s Higher Metsera Bid as Board Backs Revised Offer

Pfizer Sues Metsera and Novo Nordisk to Enforce Deal After Novo’s Higher Bid

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline